TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04025645

Intervention type: DIAGNOSTIC_TEST
Intervention: MEASUREMENT OF COMMON BILE DUCT PRESSURES
Description: THE PRESSURES OF THE COMMON BILE DUCT WERE MEASURED

Intervention type: DIAGNOSTIC_TEST
Intervention: MEASUREMENT OF COMMON BILE DUCT PRESSURES
Description: THE PRESSURES OF THE COMMON BILE DUCT WERE MEASURED
Study: NCT01140581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRONEDARONE
Description: Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRONEDARONE
Description: Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
Study: NCT00849901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 30-120 mg, PO, QD, for up to 38 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 10-40 milligram (mg), PO, QD, for up to 38 weeks
Study: NCT02172105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01207986

Intervention type: RADIATION
Group type: OTHER
Intervention: Low dose computed tomography (CT)
Study: NCT03943238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs
Description: Living donor kidney transplant recipients will receive after a preparatory regimen of total lymphoid irradiation, total body irradiation and anti-thymocyte globulin an infusion of purified donor CD34+ of \>10 x10\^6 cells /Kg, 100 x 10\^6 donor T cell/ Kg and and an escalated dose of recipient Tregs starting at 25 x10\^6/Kg.
Study: NCT05059249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot Pack
Description: Superficial Heating

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot Pack
Description: Superficial Heating

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Traction
Description: Manual Traction for 10 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical Traction
Description: Mechanical Traction for 10 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: 3 sets of slow gentle segmental mobilizations (unilateral and posterior-anterior) with at least 10 to 15 repetitions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS for 10 minutes with hot pack

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS for 10 minutes with hot pack
Study: NCT05122208

Intervention type: DRUG
Intervention: Famotidine Tablets
Description: 160 mg/day Famotidine
Study: NCT02883452

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P13
Description: CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks (Part 1)
Study: NCT01926626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)
Study: NCT02883452

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (120 mg) by single SC injection every 2 weeks (Part 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (180 mg) by double SC 90 mg injections every 2 weeks (Part 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (240 mg) by double SC 120 mg injections every 2 weeks (Part 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 6 (Part 2)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P13
Description: CT-P13 (5 mg/kg) by IV infusion administered as a 2-hour IV infusion per dose every 8 weeks up to Week 22. From Week 30, CT-P13 (120 mg) by single SC injection every 2 weeks in patients with body weight less than 80 kg, and CT-P13 (240 mg) by double SC 120 mg injections in patients with body weight at or above 80 kg based on body weight at Week 30 (Part 2)
Study: NCT00020826

Intervention type: OTHER
Intervention: quality-of-life assessment
Description: QLQ-C30 questionnaire administered. STO22 questionnaire administered.
Study: NCT00378131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC-1291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC-1291

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03901768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: a syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: a syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: 1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
Study: NCT01926626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moclobemide
Description: Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)
Study: NCT03212573

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Description: ERAS protocol includes early oral intake and deambulation and multimodal analgesia

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Oral intake and deambulation 24h after surgery and only intravenous analgesia.
Study: NCT01856205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
Description: IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
Description: IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate.
Study: NCT03507335

Intervention type: DEVICE
Intervention: chest strap and PPG-device for monitoring the rhythm
Description: chest strap and PPG-device for monitoring the rhythm during 24 hours for both groups (atrial fibrillation and sinus)

Intervention type: DEVICE
Intervention: chest strap and PPG-device for monitoring the rhythm
Description: chest strap and PPG-device for monitoring the rhythm during 24 hours for both groups (atrial fibrillation and sinus)
Study: NCT03219710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given as 3mg/m2 IV/PO q8h.
Study: NCT01844375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate group
Description: The patients will be given 12.5% carbohydrates drink 800 mL the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The patients will be given water 800 mL to drink the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
Study: NCT02226185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine hydrochloride
Description: supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: supplement of placebo two times per day for 2-3 years
Study: NCT00002804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study: NCT03219710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given as 3mg/m2 IV/PO q8h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (\>40 kg) - Day 1 -125mg , Day 2 \& Day 3 - 80 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (\>40 kg) - Day 1 -125mg , Day 2 \& Day 3 - 80 mg PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
Study: NCT01106092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2036874A vaccine
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2036874A vaccine
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2036874A vaccine
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Zilbrix™/Hib vaccine
Description: Intramuscular, single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix™
Description: Intramuscular, single dose
Study: NCT03469869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balanced and sustainable diet
Description: the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balanced and sustainable diet
Description: the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.
Study: NCT02397018

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic umbilical cord blood
Description: Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10\^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
Study: NCT04555967

Intervention type: DEVICE
Intervention: SAPIEN 3 Ultra System
Description: Transcatheter aortic valve implantation
Study: NCT01407653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: 3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Usual care
Description: Classical care
Study: NCT02434471

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory-triggered T1w DISCO LAVA
Description: The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~1. Respiratory-triggered T1w DISCO LAVA precontrast~2. Respiratory-triggered T1w DISCO LAVA in the portal venous phase~3. Respiratory-triggered T1w DISCO LAVA in the equilibrium phase
Study: NCT01413347

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pillow
Description: bronchoscopic confirmation of double-lumen tube position with a head on a pillow

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neutral
Description: bronchoscopic confirmation of double-lumen tube position in neutral position of a head
Study: NCT01850576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Reduction Intervention
Description: STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
Study: NCT00002804

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study: NCT02921386

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Testosterone Undecanoate
Description: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Testosterone Undecanoate
Description: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Testosterone Undecanoate
Description: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Testosterone Undecanoate
Description: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Testosterone Undecanoate
Description: All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
Study: NCT01892722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Administration once weekly via i.m. injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Description: Administrated orally once daily:~0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo capsule required for double-dummy masking to blind formulations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo i.m. injection
Description: Matching placebo i.m. injection required for double-dummy masking to blind formulations.
Study: NCT01707992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered as per the dose and schedule specified in the respective arms.
Study: NCT00002804

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT01585259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anfibatide
Description: Snake venom
Study: NCT00642889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02333864

Intervention type: DEVICE
Intervention: POGO® BGMS
Description: SMBG
Study: NCT01238627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Sublingual Tablet Mint (NSTM)
Description: A single dose of an experimental NSTM, with a 36-hour washout between visits

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Sublingual Tablet Mint (NSTM)
Description: A single dose of an experimental NSTM, with a 36-hour washout between visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Nicotine Tablet
Description: A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Nicotine Tablet
Description: A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
Study: NCT04043624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: IV bolus of saline, followed by continuous infusion of saline
Study: NCT02384057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training program
Description: 1000 minutes of computerized cognitive rehabilitation with C8 sciences program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cognitive rehabilitation
Description: Same amount of conventional cognitive rehabilitation
Study: NCT01643031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
Study: NCT01707992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
Study: NCT01260558

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-Permanent-Polymer Eluting Stent
Description: due randomization sirolimus-permanent-polymer eluting stent was implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus-Polymer-free Eluting Stent
Description: due randomization sirolimus-polymer-free eluting stent was implanted
Study: NCT03404778

Intervention type: DEVICE
Intervention: Biomet Comprehensive Reverse Shoulder
Description: Designed to eliminate the potential for scapular notching, this reverse shoulder system combines a a true locking mechanism that minimized wear and oxidative breakdown with a modular central screw for secure fixation.
Study: NCT04429022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 600mg PO PO x 1 prior to surgery (in pre-op) 300mg PO BID for 7 days post op

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen 1000mg PO x1 prior to surgery (in pre-op) Acetaminophen 1000mg PO q6h x 2 days then 1000mg q6h PRN post op

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg PO q 12h x 7d post op

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30mg IV once at end of hysterectomy procedure
Study: NCT02738671

Intervention type: BEHAVIORAL
Intervention: Cognitive assessment

Intervention type: OTHER
Intervention: functional magnetic resonance imaging

Intervention type: OTHER
Intervention: functional magnetic resonance imaging

Intervention type: OTHER
Intervention: functional magnetic resonance imaging
Study: NCT04429022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paracervical block with ropivacaine
Description: 0.5% ropivacaine; 10 mL bilaterally (2 point) for total of 20mL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic injection with ropivacaine at abdominal laparoscopic port sites
Description: 0.5% ropivacaine; at all laparoscopic port sites; another 10mL ropivacaine in total

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 1mg IV PRN q3h, post op, while inpatient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 1mg IV PRN q3h, post op, while inpatient

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: To be discharged home with: 12 tabs of 5mg PRN q4h
Study: NCT02519660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/Tetracaine patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine/Prilocaine cream
Study: NCT04590001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD
Description: The MobiusHD device is a nickel-titanium device that is implanted in the internal carotid sinus using a minimally invasive approach.